HLA-DR17 and Mooren's ulcer in South India

British Journal of Ophthalmology

Volumn 92, Issue 2, 2008, Pages 179-181

  Zelefsky, J R ^a   Taylor, C J ^b,g   Srinivasan, M ^c   Peacock, S ^b   Goodman, R S ^b   Key, T ^b   Watson, P G ^b   Cunningham, E T ^d,e,f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c ARAVIND EYE HOSPITAL   (India)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HLA DQ ANTIGEN; HLA DR17 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA RODENT ULCER; CORRELATION ANALYSIS; HUMAN; INDIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AUTOIMMUNE DISEASES; CORNEAL ULCER; FEMALE; HISTOCOMPATIBILITY TESTING; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 38949216080     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.127050     Document Type: Article

References (32)

1. Mondino B. Inflammatory diseases of the peripheral cornea. Ophthalmology 1988;95:463-72.
2. Zegans M, Srinivasan M. Mooren's ulcer. Int Clin Ophthalmol 1996;36:81-8.
3. Chow CYC, Foster CS. Mooren's ulcer. Int Clin Ophthalmol 1996;36:1-13.
4. Watson PG. Pathogenesis of the corneal destructive diseases. Hong Kong J Ophthalmol 1996;1:80-9.
5. Watson PG. Management of Mooren's ulcer. Eye 1997;11:349- 56.
6. Sangwan VS, Zafirakis P, Foster CS. Mooren's ulcer: current concepts in management. Indian J Ophthalmol 1997:7-17.
7. Taylor CJ, Smith SI, Morgan CH, et al. HLA and Mooren's ulceration. Br J Ophthalmol 2000;84:72-5.
8. Bowman W. The parts concerned in the operations of the eye. 1849, Case 12, p 112. Cited by Nettleship E. Chronic serpiginous ulcer of the cornea (Mooren's ulcer). Trans Ophthalmol Soc UK 1902;22:103-4.
9. Kafkala C, Choi J, Zafirakis P, et al. Mooren ulcer: an immunopathologic study. Cornea 2006;25:667-73.
10. Gottsch JD, Liu SH, Minkovitz JB, et al. Autoimmunity to a cornea-associated stromal antigen in patients with Mooren's ulcer. Invest Ophthalmol Vis Sci 1995;36:1541-7.
11. Zhou JC, Jin XY. Immunological analysisand treatment of Mooren's ulcer with cyclosporine A applied topically. Cornea 1993;12:481-8.
12. Foster CS. Systemic immunosuppressive therapy for progressive bilateral Mooren's ulcer. Ophthalmology 1985;92:1436-9.
13. Gottsch JD, Liu SH, Stark WJ. Mooren's ulcer and evidence of stromal graft rejection after penetrating keratoplasty. Am J Ophthalmol 1992;113:412-17.
14. Scheie HG, Hicks JD. Mooren's-like ulcer in a corneal graft. Am J Ophthalmol 1957;43:385-8.
15. Arentsen JJ, Christiansen JM, Maumenee AE. Marginal ulceration after intracapsular cataract extraction. Am J Ophthalmol 1976;81:194-7.
16. Joondeph H, McCarthy W, Rabb M. Mooren's ulcer: two cases occurring after cataract extraction and treated with hydrophilic lens. Ann Ophthalmol 1976;8:187-94.
17. Salamon SM, Mondino BJ, Zaidman GW. Peripheral corneal ulcers, conjunctival ulcers and scleritis after cataract surgery. Am J Ophthalmol 1982;93:334-7.
18. Mondino BJ, Hofbauer JD, Foo's RY. Mooren's ulcer after penetrating keratoplasty. Am J Ophthalmol 1987;103:53-6.
19. Van Der Gaag R. Circulating antibodies against corneal epithelium and hookworm in patients with Mooren's ulcer from Sierra Leone. Br J Ophthalmol 1983;67:623-8.
20. Zelefsky JR, Srinivasan M, Kundu A, et al. Hookworm infestation as a risk factor for Mooren's ulcer in South India. Ophthalmology 2007;114:450-3.
21. Reveille JD. The genetic basis of autoantibody production. Autoimmun Rev 2006;5:389-98.
22. Davey MP, Rosenbaum JT. The human leukocyte antigen complex and chronic ocular inflammatory disorders. Am J Ophthalmol 2000;129:235-43.
23. Levinson RD. Immunogenetics of ocular inflammatory disease. Tissue Antigens 2007;69:105-12.
24. Srinivasan M, Zegans ME, Zelefsky JR, et al. Clinical characteristics of Mooren's ulcer in South India. Br J Ophthalmol 2007;91:570-5.
25. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225-35.
26. Olerup O, Zetterguist H. DR "low-resolution" PCR-SSP typing: a correction and an update. Tissue Antigens 1993;41:55-6.
27. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993;41:119-34.
28. Harding C. Cellular and molecular aspects of antigen processing and the function of class II MHC molecules. Am J Respir Cell Mol Biol 1993;8:461-7.
29. Oruc S, Duffy BF, Mohanakumar T, et al. The association of HLA class II with pars planitis. Am J Ophthalmol 2001;131:657-9.
30. Tjernstrom F, Hellmer G, Nived O, et al. Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus. Lupus 1999;8:103-8.
31. Berlin M, Fogdell-Hahn A, Olerup O, et al. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997;156:1601-5.
32. Forneau JM, Bach JM, Van Endert PM, et al. The elusive case for a role of mimicry in autoimmune diseases. Mol Immunol 2004;40:1095-102.